Risperidone in Children with Autism and Serious Behavioral Problems
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Atypical antipsychotic agents, which block postsynaptic dopamine and serotonin receptors, have advantages over traditional antipsychotic medications in the treatment of adults with schizophrenia and may be beneficial in children with autistic disorder who have serious behavioral disturbances. However, data on the safety and efficacy of atypical antipsychotic agents in children are limited. METHODS: We conducted a multisite, randomized, double-blind trial of risperidone as compared with placebo for the treatment of autistic disorder accompanied by severe tantrums, aggression, or self-injurious behavior in children 5 to 17 years old. The primary outcome measures were the score on the Irritability subscale of the Aberrant Behavior Checklist and the rating on the Clinical Global Impressions - Improvement (CGI-I) scale at eight weeks. RESULTS: A total of 101 children (82 boys and 19 girls; mean [+/-SD] age, 8.8+/-2.7 years) were randomly assigned to receive risperidone (49 children) or placebo (52). Treatment with risperidone for eight weeks (dose range, 0.5 to 3.5 mg per day) resulted in a 56.9 percent reduction in the Irritability score, as compared with a 14.1 percent decrease in the placebo group (P<0.001). The rate of a positive response, defined as at least a 25 percent decrease in the Irritability score and a rating of much improved or very much improved on the CGI-I scale, was 69 percent in the risperidone group (34 of 49 children had a positive response) and 12 percent in the placebo group (6 of 52, P<0.001). Risperidone therapy was associated with an average weight gain of 2.7+/-2.9 kg, as compared with 0.8+/-2.2 kg with placebo (P<0.001). Increased appetite, fatigue, drowsiness, dizziness, and drooling were more common in the risperidone group than in the placebo group (P<0.05 for each comparison). In two thirds of the children with a positive response to risperidone at eight weeks (23 of 34), the benefit was maintained at six months. CONCLUSIONS: Risperidone was effective and well tolerated for the treatment of tantrums, aggression, or self-injurious behavior in children with autistic disorder. The short period of this trial limits inferences about adverse effects such as tardive dyskinesia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Methylphenidate, atomoxetine and guanfacine are beneficial for ADHD symptoms in ASD (Table 2 204 -206 )”
From Autism spectrum disorder (2020) · cites this paper as [206]
In the citing paper
“Currently, only two drugs have been approved by the United States (U.S.) Food and Drug Administration (FDA) for use in the ASD population: risperidone [23] and aripiprazole [24]. Both drugs are approved for the treatment of irritability in children and adolescents with ASD.”
From Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms (2025) · cites this paper as [23]
In the citing paper
“as the two drugs that have received FDA approval for use in ASD, risperidone, and aripiprazole, are both for the indication of “irritability” [23, 24]”
From Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms (2025) · cites this paper as [23]
In the citing paper
“risperidone and aripiprazole, which are both FDA-approved for irritability in children and adolescents with ASD [23, 24].”
From Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms (2025) · cites this paper as [23]
In the citing paper
“and significant improvement in core autism symptoms [601-604].”
From Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings (2012) · cites this paper as [601]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Littell, R. C. (1996) · Medical Entomology and Zoology · Cited by 10,547
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
SIMPSON, G. M., B., M., B., G., ANGUS, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,264
ECDEU Assessment Manual: (591322011-001)
Guy, W. (1976) · PsycEXTRA Dataset · doi:10.1037/e591322011-001 · Cited by 1,896
Kapur, S., & Seeman, P. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.3.360 · Cited by 1,140
Pervasive Developmental Disorders in preschool children
Chakrabarti, S. (2001) · JAMA · doi:10.1001/jama.285.24.3093 · Cited by 1,132
Gibbons, R. D. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820210073009 · Cited by 719
McDougle, C. J., Holmes, J. P., Carlson, D. C., Pelton, G. H., Cohen, D. J., & Price, L. H. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.7.633 · Cited by 427
Self-citationDiagnosing Autism: Analyses of Data from the Autism Diagnostic Interview
Lord, C., Pickles, A., McLennan, J., Rutter, M., Bregman, J., Folstein, S., Fombonne, E., Leboyer, M., & Minshew, N. (1997) · Journal of Autism and Developmental Disorders · doi:10.1023/a:1025873925661 · Cited by 373
The Vineland Adaptive Behavior Scales: Supplementary Norms for Individuals with Autism
Carter, A. S., Volkmar, F. R., Sparrow, S. S., Wang, J.-J., Lord, C., Dawson, G., Fombonne, E., Loveland, K., Mesibov, G., & Schopler, E. (1998) · Journal of Autism and Developmental Disorders · doi:10.1023/a:1026056518470 · Cited by 367
Self-citation
Cited by
Lord, C., Brugha, T. S., Charman, T., Cusack, J., Dumas, G., Frazier, T., Jones, E. J. H., Jones, R. M., Pickles, A., State, M. W., et al. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0138-4 · Cited by 1,859
Comorbid psychiatric disorders in children with autism: interview development and rates of disorders
Leyfer, O. T., Folstein, S. E., Bacalman, S., Davis, N. O., Dinh, E., Morgan, J., Tager-Flusberg, H., & Lainhart, J. E. (2006) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-006-0123-0 · Cited by 1,637
“They are the Aberrant Behavior Checklist (Aman, Singh, Stewart, & Field, 1985; McCracken et al., 2002; Rojahn, Aman, Matson, & Mayville, 2003), the Developmental Behavior Checklist (Clarke, Tonge, Einfeld, & Mackinnon, 2003; Dekker, Nunn, Einfeld, Tonge, & Koot, 2002b; Einfeld, Tonge, Turner, Parmenter, & Smith, 1999;…”
Identification, Evaluation, and Management of Children With Autism Spectrum Disorder
Hyman, S. L., Levy, S. E., Myers, S. M., COUNCIL ON CHILDREN WITH DISABILITIES, S. O. D. A. B. P., Kuo, D. Z., Apkon, S., Davidson, L. F., Ellerbeck, K. A., Foster, J. E. A., Noritz, G. H., et al. (2020) · Pediatrics · doi:10.1542/peds.2019-3447 · Cited by 1,798
Evidence-Based Psychosocial Treatments for Children and Adolescents With Disruptive Behavior
Eyberg, S. M., Nelson, M. M., & Boggs, S. R. (2008) · Journal of Clinical Child & Adolescent Psychology · doi:10.1080/15374410701820117 · Cited by 1,335
“…aggression have found the atypical antipsychotic drug risperidone effective for reducing aggressive behaviors in youth with CD (Findling et al., 2000), with below-average IQ (Aman et al., 2002; Buitelaar, van der Gaag, Cohen-Kettenis, & Melman, 2001), and with autism (McCracken et al., 2002).”
BackgroundSecond-Generation (Atypical) Antipsychotics and Metabolic Effects: A Comprehensive Literature Review
Newcomer, J. W. (2005) · CNS Drugs · doi:10.2165/00023210-200519001-00001 · Cited by 1,340
Management of Children With Autism Spectrum Disorders
Myers, S. M., Johnson, C. P., & the Council on Children With Disabilities (2007) · Pediatrics · doi:10.1542/peds.2007-2362 · Cited by 1,125
The health status of adults on the autism spectrum
Croen, L. A., Zerbo, O., Qian, Y., Massolo, M. L., Rich, S., Sidney, S., & Kripke, C. (2015) · Autism · doi:10.1177/1362361315577517 · Cited by 1,110
“Antipsychotics use in autistic children has been associated with significantly increased weight gain compared to placebo controls (McCracken et al., 2002; Shea et al., 2004).”
BackgroundAn Overview of Autism Spectrum Disorder, Heterogeneity and Treatment Options
Masi, A., DeMayo, M. M., Glozier, N., & Guastella, A. J. (2017) · Neuroscience Bulletin · doi:10.1007/s12264-017-0100-y · Cited by 987
“Risperidone, which acts by blocking the brain’s receptors for dopamine and serotonin, was found to be safe and effective for short-term treatment, with improvements observed in stereotypic behavior and hyperactivity [108].”
BackgroundEvidence-Based Comprehensive Treatments for Early Autism
Rogers, S. J., & Vismara, L. A. (2008) · Journal of Clinical Child & Adolescent Psychology · doi:10.1080/15374410701817808 · Cited by 984
Autism and the pervasive developmental disorders
Volkmar, F. R., & Klin, A. (2012) · New Oxford Textbook of Psychiatry · doi:10.1093/med/9780199696758.003.0214 · Cited by 939
Self-citationThe Role of Emotion Regulation in Autism Spectrum Disorder
Mazefsky, C. A., Herrington, J., Siegel, M., Scarpa, A., Maddox, B. B., Scahill, L., & White, S. W. (2013) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2013.05.006 · Cited by 881
“Application of a validated dimensional measurement reflecting an emotional and behavioral composite, termed irritability,(94) in randomized clinical trials led to Food and Drug Administration approval of 2 medications in children with DSM-IV–defined autistic disorder.(95,96) These successful drug treatment programs po…”
Self-citationVolkmar, F., Siegel, M., Woodbury-Smith, M., King, B., McCracken, J., & State, M. (2014) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2013.10.013 · Cited by 848
Self-citationHagerman, R. J., Berry-Kravis, E., Hazlett, H. C., Bailey, D. B., Moine, H., Kooy, R. F., Tassone, F., Gantois, I., Sonenberg, N., Mandel, J. L., et al. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.65 · Cited by 838
Behavior Therapy for Children With Tourette Disorder: A Randomized Controlled Trial
Piacentini, J., Woods, D. W., Scahill, L., Wilhelm, S., Peterson, A. L., Chang, S., Ginsburg, G. S., Deckersbach, T., Dziura, J., Levi-Pearl, S., et al. (2010) · JAMA · doi:10.1001/jama.2010.607 · Cited by 790
Self-citationAutism Spectrum Disorder: Classification, diagnosis and therapy
Sharma, S. R., Gonda, X., & Tarazi, F. I. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.05.007 · Cited by 673
“Risperidone treatment also significantly improved aggression, social withdrawal, repetitive behaviors, and hyperactivity (McCracken et al., 2002).”
Autism and pervasive developmental disorders
Volkmar, F. R., Lord, C., Bailey, A., Schultz, R. T., & Klin, A. (2004) · Journal of Child Psychology and Psychiatry · doi:10.1046/j.0021-9630.2003.00317.x · Cited by 616
Self-citationAripiprazole in the Treatment of Irritability in Children and Adolescents With Autistic Disorder
Owen, R., Sikich, L., Marcus, R. N., Corey-Lisle, P., Manos, G., McQuade, R. D., Carson, W. H., & Findling, R. L. (2009) · Pediatrics · doi:10.1542/peds.2008-3782 · Cited by 613
Leekam, S. R., Prior, M. R., & Uljarevic, M. (2011) · Psychological Bulletin · doi:10.1037/a0023341 · Cited by 612
“In one study (McCracken et al., 2002), 101 children (mean age, 8.”
BackgroundMethodInfluentialAdvances in the Treatment of Fragile X Syndrome
Hagerman, R. J., Berry-Kravis, E., Kaufmann, W. E., Ono, M. Y., Tartaglia, N., Lachiewicz, A., Kronk, R., Delahunty, C., Hessl, D., Visootsak, J., et al. (2009) · Pediatrics · doi:10.1542/peds.2008-0317 · Cited by 596
National Trends in the Outpatient Treatment of Children and Adolescents With Antipsychotic Drugs
Olfson, M., Blanco, C., Liu, L., Moreno, C., & Laje, G. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.6.679 · Cited by 591
Shea, S., Turgay, A., Carroll, A., Schulz, M., Orlik, H., Smith, I., & Dunbar, F. (2004) · Pediatrics · doi:10.1542/peds.2003-0264-f · Cited by 566
Severe Mood Dysregulation, Irritability, and the Diagnostic Boundaries of Bipolar Disorder in Youths
Leibenluft, E. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.10050766 · Cited by 565
Marcus, R. N., Owen, R., Kamen, L., Manos, G., McQuade, R. D., Carson, W. H., & Aman, M. G. (2009) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e3181b76658 · Cited by 566
Self-citationThe serotonin system in autism spectrum disorder: From biomarker to animal models
Muller, C. L., Anacker, A. M. J., & Veenstra-VanderWeele, J. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2015.11.010 · Cited by 531
“More consistent data supports the use of risperidone and aripiprazole (McCracken et al., 2002, McDougle et al., 2005), atypical antipsychotic medications with antagonism at multiple monoamine receptors, including the serotonin receptor 5-HT2A.”
BackgroundSukhodolsky, D. G., Scahill, L., Gadow, K. D., Arnold, L. E., Aman, M. G., McDougle, C. J., McCracken, J. T., Tierney, E., Williams White, S., Lecavalier, L., et al. (2008) · Journal of Abnormal Child Psychology · doi:10.1007/s10802-007-9165-9 · Cited by 518
Self-citationKing, B. H., Hollander, E., Sikich, L., McCracken, J. T., Scahill, L., Bregman, J. D., Donnelly, C. L., Anagnostou, E., Dukes, K., Sullivan, L., et al. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.30 · Cited by 482
Self-citationMcDougle, C. J., Scahill, L., Aman, M. G., McCracken, J. T., Tierney, E., Davies, M., Arnold, L. E., Posey, D. J., Martin, A., Ghuman, J. K., et al. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.6.1142 · Cited by 482
Self-citationGeller, B., Tillman, R., Craney, J. L., & Bolhofner, K. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.5.459 · Cited by 475
Joshi, G., Petty, C., Wozniak, J., Henin, A., Fried, R., Galdo, M., Kotarski, M., Walls, S., & Biederman, J. (2010) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-010-0996-9 · Cited by 464
Bearss, K., Johnson, C., Smith, T., Lecavalier, L., Swiezy, N., Aman, M., McAdam, D. B., Butter, E., Stillitano, C., Minshawi, N., et al. (2015) · JAMA · doi:10.1001/jama.2015.3150 · Cited by 454
Self-citationOlfson, M., Blanco, C., Wang, S., Laje, G., & Correll, C. U. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.3074 · Cited by 449
Silverman, J. L., Tolu, S. S., Barkan, C. L., & Crawley, J. N. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.201 · Cited by 438
“…to treat irritability associated with autistic disorder in children and adolescents ages 5 to 16 years, including symptoms of aggression towards others, deliberate self-injuriousness, temper tantrums, and quickly changing moods (McCracken et al , 2002; McDougle et al , 1997; McDougle et al , 2005).”
Joshi, G., Wozniak, J., Petty, C., Martelon, M. K., Fried, R., Bolfek, A., Kotte, A., Stevens, J., Furtak, S. L., Bourgeois, M., et al. (2013) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-012-1679-5 · Cited by 419
Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD)
Williams, K., Brignell, A., Randall, M., Silove, N., & Hazell, P. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004677.pub3 · Cited by 415
Hollander, E., Phillips, A., Chaplin, W., Zagursky, K., Novotny, S., Wasserman, S., & Iyengar, R. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300627 · Cited by 408
“The composite measure more closely parallels the way the CGI-AD measure has been used in other trials (Research Units on Pediatric Psychopharmacology (RUPP) Autism Network, 2002) where the focus was on global behavior, rather than core features of autism such as language and social reciprocity.”
BackgroundMethodInfluentialChallenges in Evaluating Psychosocial Interventions for Autistic Spectrum Disorders
Lord, C., Wagner, A., Rogers, S., Szatmari, P., Aman, M., Charman, T., Dawson, G., Durand, V. M., Grossman, L., Guthrie, D., et al. (2005) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-005-0017-6 · Cited by 382
Self-citationAntipsychotic-associated weight gain: management strategies and impact on treatment adherence
Dayabandara, M., Hanwella, R., Ratnatunga, S., Seneviratne, S., Suraweera, C., & de Silva, V. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s113099 · Cited by 367
“Peer perception too plays a significant role.(31) Changes in the physical appearance can lead to body image issues and problems with self-esteem, which in turn could lead to poor compliance with medication.”
BackgroundDiagnosis and management of Cornelia de Lange syndrome: first international consensus statement
Kline, A. D., Moss, J. F., Selicorni, A., Bisgaard, A.-M., Deardorff, M. A., Gillett, P. M., Ishman, S. L., Kerr, L. M., Levin, A. V., Mulder, P. A., et al. (2018) · Nature Reviews Genetics · doi:10.1038/s41576-018-0031-0 · Cited by 367
Self-citationAman, M. G., Mcdougle, C. J., Scahill, L., Handen, B., Arnold, L. E., Johnson, C., Stigler, K. A., Bearss, K., Butter, E., Swiezy, N. B., et al. (2009) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e3181bfd669 · Cited by 371
Self-citationDe Hert, M., Dobbelaere, M., Sheridan, E. M., Cohen, D., & Correll, C. U. (2011) · European Psychiatry · doi:10.1016/j.eurpsy.2010.09.011 · Cited by 362
“In addition, risperidone (age 5– 17 years) and aripiprazole (aged 6–17 years) are approved for the treatment of irritability and aggression in youth with autistic disorder [82,85,94,104].”
BackgroundInfluentialA placebo-controlled trial of risperidone in Tourette syndrome
Scahill, L., Leckman, J. F., Schultz, R. T., Katsovich, L., & Peterson, B. S. (2003) · Neurology · doi:10.1212/01.wnl.0000055434.39968.67 · Cited by 362
Self-citationA Systematic Review of Medical Treatments for Children With Autism Spectrum Disorders
McPheeters, M. L., Warren, Z., Sathe, N., Bruzek, J. L., Krishnaswami, S., Jerome, R. N., & Veenstra-VanderWeele, J. (2011) · Pediatrics · doi:10.1542/peds.2011-0427 · Cited by 356
Amminger, G. P., Berger, G. E., Schäfer, M. R., Klier, C., Friedrich, M. H., & Feucht, M. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.05.007 · Cited by 355
Tyrer, P., Oliver-Africano, P. C., Ahmed, Z., Bouras, N., Cooray, S., Deb, S., Murphy, D., Hare, M., Meade, M., Reece, B., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60072-0 · Cited by 348
Howes, O. D., Rogdaki, M., Findon, J. L., Wichers, R. H., Charman, T., King, B. H., Loth, E., McAlonan, G. M., McCracken, J. T., Parr, J. R., et al. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881117741766 · Cited by 342
“Similarly, a large multi-site study reported a 57% reduction in irritability (effect size=1.2; McCracken et al., 2002).”
InfluentialSelf-citationDrug development for neurodevelopmental disorders: lessons learned from fragile X syndrome
Berry-Kravis, E. M., Lindemann, L., Jønch, A. E., Apostol, G., Bear, M. F., Carpenter, R. L., Crawley, J. N., Curie, A., Des Portes, V., Hossain, F., et al. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.221 · Cited by 336
Berry-Kravis, E. M., Hessl, D., Rathmell, B., Zarevics, P., Cherubini, M., Walton-Bowen, K., Mu, Y., Nguyen, D. V., Gonzalez-Heydrich, J., Wang, P. P., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004214 · Cited by 328
FARZIN, F., PERRY, H., HESSL, D., LOESCH, D., COHEN, J., BACALMAN, S., GANE, L., TASSONE, F., HAGERMAN, P., & HAGERMAN, R. (2006) · Journal of Developmental & Behavioral Pediatrics · doi:10.1097/00004703-200604002-00012 · Cited by 325
Solmi, M., Fornaro, M., Ostinelli, E. G., Zangani, C., Croatto, G., Monaco, F., Krinitski, D., Fusar‐Poli, P., & Correll, C. U. (2020) · World Psychiatry · doi:10.1002/wps.20765 · Cited by 324
Neurochemical correlates of autistic disorder: a review of the literature
Lam, K. S. L., Aman, M. G., & Arnold, L. E. (2006) · Research in Developmental Disabilities · doi:10.1016/j.ridd.2005.03.003 · Cited by 318
Self-citationSikich, L., Hamer, R. M., Bashford, R. A., Sheitman, B. B., & Lieberman, J. A. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300327 · Cited by 308
“…controlled studies of atypical agents have been conducted for the treatment of disruptive behaviors in autism spectrum disorders (Malone et al, 2001; McCracken et al, 2002) and conduct disorder in youth with low or subnormal intelligence (Findling et al, 2000; Aman et al, 2002; Snyder et al, 2002).”
BackgroundContemporary assessment and pharmacotherapy of Tourette syndrome
Scahill, L., Erenberg, G., Berlin, C. M., Budman, C., Coffey, B. J., Jankovic, J., Kiessling, L., King, R. A., Kurlan, R., Lang, A., et al. (2006) · NeuroRX · doi:10.1016/j.nurx.2006.01.009 · Cited by 300
Self-citationDichter, G. S., Damiano, C. A., & Allen, J. A. (2012) · Journal of Neurodevelopmental Disorders · doi:10.1186/1866-1955-4-19 · Cited by 299
“core autism symptoms [601-604].”
Intranasal Oxytocin in Children and Adolescents with Autism Spectrum Disorder
Sikich, L., Kolevzon, A., King, B. H., McDougle, C. J., Sanders, K. B., Kim, S.-J., Spanos, M., Chandrasekhar, T., Trelles, M. D. P., Rockhill, C. M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103583 · Cited by 298
Self-citationIncidence of Gastrointestinal Symptoms in Children With Autism: A Population-Based Study
Ibrahim, S. H., Voigt, R. G., Katusic, S. K., Weaver, A. L., & Barbaresi, W. J. (2009) · PEDIATRICS · doi:10.1542/peds.2008-2933 · Cited by 298
Psychotropic medication use among Medicaid-enrolled children with autism spectrum disorders
Mandell, D. S., Morales, K. H., Marcus, S. C., Stahmer, A. C., Doshi, J., & Polsky, D. E. (2008) · Pediatrics · doi:10.1542/peds.2007-0984 · Cited by 295
Nankova, B. B., Agarwal, R., MacFabe, D. F., & La Gamma, E. F. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103740 · Cited by 294
“Furthermore, it provides a possible molecular mechanism to account for the hyperactivation of the mesocortical dopamine system suggested in several clinical reports of ASD [97,98] and in animal models of ASD [66,99].”
BackgroundFung, L. K., Mahajan, R., Nozzolillo, A., Bernal, P., Krasner, A., Jo, B., Coury, D., Whitaker, A., Veenstra-Vanderweele, J., & Hardan, A. Y. (2016) · Pediatrics · doi:10.1542/peds.2015-2851k · Cited by 294
A Dopamine Hypothesis of Autism Spectrum Disorder
Pavăl, D. (2017) · Developmental Neuroscience · doi:10.1159/000478725 · Cited by 294
Health Care Utilization and Expenditures for Children with Autism: Data from U.S. National Samples
Liptak, G. S., Stuart, T., & Auinger, P. (2006) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-006-0119-9 · Cited by 288
Volkmar, F. R., & Pauls, D. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14471-6 · Cited by 290
Self-citationResearch Units on Pediatric Psychopharmacology Autism Network (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.7.1361 · Cited by 288
Mayes, S. D., Calhoun, S. L., Murray, M. J., Ahuja, M., & Smith, L. A. (2011) · Research in Autism Spectrum Disorders · doi:10.1016/j.rasd.2010.06.012 · Cited by 287
Aggression in autism spectrum disorder: presentation and treatment options
Fitzpatrick, S., Srivorakiat, L., Wink, L., Pedapati, E., & Erickson, C. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s84585 · Cited by 271
“In 2002, the Research Units on Pediatric Psychopharmacology (RUPP) Autism Network published the results of an 8-week, randomized, double-blind, placebo-controlled trial of risperidone in 101 youth (5–17 years) with ASD and comorbid aggression.(46) In this trial, subjects treated with risperidone had a significant decr…”
Validity of the Aberrant Behavior Checklist in Children with Autism Spectrum Disorder
Kaat, A. J., Lecavalier, L., & Aman, M. G. (2014) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-013-1970-0 · Cited by 271
Self-citationBryson, S. E., Rogers, S. J., & Fombonne, E. (2003) · The Canadian Journal of Psychiatry · doi:10.1177/070674370304800802 · Cited by 285
“8 years) presenting with clinical levels of tantrums, aggression, and self-injurious behaviour (89).”
The developmental psychopathology of irritability
Leibenluft, E., & Stoddard, J. (2013) · Development and Psychopathology · doi:10.1017/s0954579413000722 · Cited by 274
“For example, one trial resulted in an FDA indication for risperidone in the treatment of irritability in youths with autism (McCracken et al., 2002).”
BackgroundAutism spectrum disorders: Concurrent clinical disorders
Ming, X., Brimacombe, M., Chaaban, J., Zimmerman-Bier, B., & Wagner, G. C. (2008) · Journal of Child Neurology · doi:10.1177/0883073807307102 · Cited by 266
“Sleep disorders 35 (42) 35 (42) 13 (16) 83 Food intolerance 37 (45) 30 (37) 14 (17) 81 Gastrointestinal dysfunction 45 (49) 39 (41) 10 (10) 94 Epilepsy 5 (23) 8 (36) 9 (41) 22 Mood disorders 11 (26) 21 (50) 10 (24) 42 Aggression/self-injury 24 (47) 17 (33) 10 (20) 51”
Current Enlightenment About Etiology and Pharmacological Treatment of Autism Spectrum Disorder
Eissa, N., Al-Houqani, M., Sadeq, A., Ojha, S. K., Sasse, A., & Sadek, B. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00304 · Cited by 260
“The antipsychotic medication with risperidone is mainly approached in ASD patients with SCH, bipolar disorder, and/or irritability symptoms, as this drug has revealed to be better than placebo in treating irritability, repetitive behavior, aggression, anxiety, depression and nervousness (McDougle et al., 1998b; McCrac…”
BackgroundInfluentialNutt, D. J., Fone, K., Asherson, P., Bramble, D., Hill, P., Matthews, K., Morris, K. A., Santosh, P., Sonuga-Barke, E., Taylor, E., et al. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881106073219 · Cited by 259
“Conversely, the effect of atypical antipsychotics on ADHD symptoms particularly hyperactivity in ASD is good, with an effect size of 1.4 (McCracken et al., 2002 Ia).”
BackgroundInfluentialAntipsychotic Use in Children and Adolescents: Minimizing Adverse Effects to Maximize Outcomes
CORRELL, C. U. (2008) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e31815b5cb1 · Cited by 254
The Emerging Picture of Autism Spectrum Disorder: Genetics and Pathology
Chen, J. A., Peñagarikano, O., Belgard, T. G., Swarup, V., & Geschwind, D. H. (2015) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012414-040405 · Cited by 254
Treatment of Young People With Antipsychotic Medications in the United States
Olfson, M., King, M., & Schoenbaum, M. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.0500 · Cited by 249
Lai, M.-C., Anagnostou, E., Wiznitzer, M., Allison, C., & Baron-Cohen, S. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30034-x · Cited by 250
Faras, H., Al Ateeqi, N., & Tidmarsh, L. (2010) · Annals of Saudi Medicine · doi:10.4103/0256-4947.65261 · Cited by 227
Exploring the Validity of Valproic Acid Animal Model of Autism
Mabunga, D. F. N., Gonzales, E. L. T., Kim, J.-W., Kim, K. C., & Shin, C. Y. (2015) · Experimental Neurobiology · doi:10.5607/en.2015.24.4.285 · Cited by 247
“Consequentially, there is only one ASD-specific drug approved by the Food and Drug Administration (FDA) to treat the irritability symptoms and, to some extent, repetitive behaviors; but not social communication problems [11-13].”
BackgroundPsychopharmacological Treatment for Very Young Children: Contexts and Guidelines
GLEASON, M. M., EGGER, H. L., EMSLIE, G. J., GREENHILL, L. L., KOWATCH, R. A., LIEBERMAN, A. F., LUBY, J. L., OWENS, J., SCAHILL, L. D., SCHEERINGA, M. S., et al. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e3181570d9e · Cited by 244
Self-citationSocial Skills Training for Adolescents with Asperger Syndrome and High-Functioning Autism
Tse, J., Strulovitch, J., Tagalakis, V., Meng, L., & Fombonne, E. (2007) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-006-0343-3 · Cited by 240
Gastrointestinal symptoms in a sample of children with pervasive developmental disorders
Nikolov, R. N., Bearss, K. E., Lettinga, J., Erickson, C., Rodowski, M., Aman, M. G., McCracken, J. T., McDougle, C. J., Tierney, E., Vitiello, B., et al. (2009) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-008-0637-8 · Cited by 240
Self-citationIrritability in Children and Adolescents
Brotman, M. A., Kircanski, K., & Leibenluft, E. (2017) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-032816-044941 · Cited by 232
“Risperidone and aripiprazole, second-generation antipsychotics, are the only pharmacological agents that have received US Food and Drug Administration indication for the treatment of irritability, but the indication is specific to the presence of autism (Marcus et al. 2009, McCracken et al. 2002).”
Taliou, A., Zintzaras, E., Lykouras, L., & Francis, K. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.04.006 · Cited by 233
Cognitive-Behavioral Therapy for Anxiety in Children With High-Functioning Autism: A Meta-analysis
Sukhodolsky, D. G., Bloch, M. H., Panza, K. E., & Reichow, B. (2013) · Pediatrics · doi:10.1542/peds.2013-1193 · Cited by 234
Autism spectrum disorder: advances in evidence-based practice
Anagnostou, E., Zwaigenbaum, L., Szatmari, P., Fombonne, E., Fernandez, B. A., Woodbury-Smith, M., Brian, J., Bryson, S., Smith, I. M., Drmic, I., et al. (2014) · Canadian Medical Association Journal · doi:10.1503/cmaj.121756 · Cited by 233
“For individuals aged more than five years, large clinical trials have addressed the efficacy and safety of the major classes of medications used in the clinic.(69,70,71) A few systematic reviews are available supporting the use of pharmacologic agents for associated symptoms.”
BackgroundMethodAn Update on Psychopharmacological Treatment of Autism Spectrum Disorder
Aishworiya, R., Valica, T., Hagerman, R., & Restrepo, B. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01183-1 · Cited by 233
“There are two medications approved by the FDA for the treatment of irritability associated with ASD: risperidone, approved for children older than 5 years of age [40], and aripiprazole, approved for children 6 to 17 years of age [41]; clinical trials found them to be effective in reducing irritability and, to a lesser…”
BackgroundHollander, E., Chaplin, W., Soorya, L., Wasserman, S., Novotny, S., Rusoff, J., Feirsen, N., Pepa, L., & Anagnostou, E. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.202 · Cited by 224
“For this reason, this domain has been the target of clinical trials, mostly focused on the use of atypical antipsychotics, (McCracken et al 2002), but also early studies of anticonvulsants, such as valproate, psychostimulants, and α - and β -adrenergic agonists.”
Haas, M., DelBello, M. P., Pandina, G., Kushner, S., Van Hove, I., Augustyns, I., Quiroz, J., & Kusumakar, V. (2009) · Bipolar Disorders · doi:10.1111/j.1399-5618.2009.00750.x · Cited by 231
Esbensen, A. J., Greenberg, J. S., Seltzer, M. M., & Aman, M. G. (2009) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-009-0750-3 · Cited by 224
Self-citationOpen-label add-on treatment trial of minocycline in fragile X syndrome.
Paribello, C., Tao, L., Folino, A., Berry-Kravis, E., Tranfaglia, M., Ethell, I. M., & Ethell, D. W. (2010) · BMC Neurology · doi:10.1186/1471-2377-10-91 · Cited by 223
“This methodology involves a parent-defined target behaviour and has been utilized and validated in the RUPP clinical trials particularly for the risperidone studies in autism [28,30].”
BackgroundMethodCannabinoid treatment for autism: a proof-of-concept randomized trial
Aran, A., Harel, M., Cassuto, H., Polyansky, L., Schnapp, A., Wattad, N., Shmueli, D., Golan, D., & Castellanos, F. X. (2021) · Molecular Autism · doi:10.1186/s13229-021-00420-2 · Cited by 223
“defined as a rating of ‘much improved’ or ’very much improved’ [34].”
BackgroundMethodInfluentialBALB/c mice: Low sociability and other phenotypes that may be relevant to autism
BRODKIN, E. (2007) · Behavioural Brain Research · doi:10.1016/j.bbr.2006.06.025 · Cited by 223
Stringaris, A., Vidal‐Ribas, P., Brotman, M. A., & Leibenluft, E. (2018) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.12823 · Cited by 220
Vitiello, B., Correll, C., van Zwieten-Boot, B., Zuddas, A., Parellada, M., & Arango, C. (2009) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2009.04.008 · Cited by 222
Self-citationWong, H. H. L., & Smith, R. G. (2006) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-006-0131-0 · Cited by 224
Progress toward treatments for synaptic defects in autism
Delorme, R., Ey, E., Toro, R., Leboyer, M., Gillberg, C., & Bourgeron, T. (2013) · Nature Medicine · doi:10.1038/nm.3193 · Cited by 218
ARNOLD, L. E., VITIELLO, B., MCDOUGLE, C., SCAHILL, L., SHAH, B., GONZALEZ, N. M., CHUANG, S., DAVIES, M., HOLLWAY, J., AMAN, M. G., et al. (2003) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200312000-00011 · Cited by 218
Self-citationAn update on pharmacotherapy for autism spectrum disorder in children and adolescents
Ji, N. Y., & Findling, R. L. (2015) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000132 · Cited by 217
Open-Label Treatment Trial of Lithium to Target the Underlying Defect in Fragile X Syndrome
Berry-Kravis, E., Sumis, A., Hervey, C., Nelson, M., Porges, S. W., Weng, N., Weiler, I. J., & Greenough, W. T. (2008) · Journal of Developmental & Behavioral Pediatrics · doi:10.1097/dbp.0b013e31817dc447 · Cited by 215
Risperidone in Children With Autism: Randomized, Placebo-Controlled, Double-Blind Study
Nagaraj, R., Singhi, P., & Malhi, P. (2006) · Journal of Child Neurology · doi:10.1177/08830738060210060801 · Cited by 214
Trends in Antipsychotic Drug Use by Very Young, Privately Insured Children
Olfson, M., Crystal, S., Huang, C., & Gerhard, T. (2010) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2009.09.003 · Cited by 215
Anagnostou, E., Jones, N., Huerta, M., Halladay, A. K., Wang, P., Scahill, L., Horrigan, J. P., Kasari, C., Lord, C., Choi, D., et al. (2015) · Autism · doi:10.1177/1362361314542955 · Cited by 210
Self-citation
Metadata
- Authors
- McCracken, J. T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M. G., Arnold, L. E., Lindsay, R., Nash, P., Hollway, J., McDougle, C. J., Posey, D., Swiezy, N., Kohn, A., Scahill, L., Martin, A., Koenig, K., Volkmar, F., Carroll, D., Lancor, A., Tierney, E., Ghuman, J., Gonzalez, N. M., Grados, M., Vitiello, B., Ritz, L., Davies, M., Robinson, J., & McMahon, D.
- Affiliations
- University of California, Los Angeles (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2002-08
- Volume
- 347
- Issue
- 5
- Pages
- 314-321
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1968430210
- Cited by
- 1,574
- References
- 25
- Citations by year
- 2026: 50 · 2025: 68 · 2024: 54 · 2023: 43 · 2022: 51 · 2021: 77 · 2020: 54 · 2019: 43 · 2018: 69 · 2017: 56 · 2016: 57 · 2015: 59 · 2014: 57 · 2013: 88 · 2012: 88
- FWCI
- 30.55
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Funders
- National Institutes of Health (n01mh070009-000, n01mh070001-008, n01mh070010-001, n01mh080011-005)
- National Institute of Mental Health (N01-MH-80011, N01 MH 70010, K23MH001883, N01 MH-70001, N01 MH 70009)
- National Center for Research Resources (M01-RR 00750, M01 RR-00052, M01-RR-00034, M01RR000750, M01RR000052, M01RR000034)
- Topics
- Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Social Sciences › Psychology › Developmental and Educational Psychology › Behavioral and Psychological Studies
- Keywords
- risperidone, autism spectrum disorder, atypical antipsychotics, irritability, tantrums, aggression, self-harm, Aberrant Behavior Checklist, weight gain, adverse effects, children
- MeSH terms
- Adolescent, Autistic Disorder, Child, Child Behavior, Child, Preschool, Double-Blind Method, Female, Humans, Male, Antipsychotic Agents, Treatment Outcome, Risperidone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.